Positive Results For Empagliflozin In Type 1 Diabetes Trials | Latest News RSS feed

Positive Results For Empagliflozin In Type 1 Diabetes Trials - Latest News


Researchers report positive trial results for new diabetes treatment

A study in JCI Insight showed that a treatment based on the interleukin-2 protein worked best among type 1 diabetes patients when administered every three days. UK researchers analyzed the blood sampl... read more

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

and INDIANAPOLIS, Oct. 10, 2018 /PRNewswire/ -- Novel results based on data from the landmark EMPA-REG OUTCOME® trial ... disease. JARDIANCE is not for people with type 1 diabetes or for people ... read more

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with ...

Today, the journal Circulation published novel results based on ... in the EMPA-REG OUTCOME ® trial. Empagliflozin is not approved for people with type 1 diabetes. About Boehringer Ingelheim ... read more

Looking for another news?


Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

INGELHEIM, Germany and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials ... in adults with type 1 diabetes on empagliflo... read more


Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

“These positive Phase 2 data show clinically relevant efficacy, favorable safety profile and dose responsive results in line with our expectations for this proof-of-concept trial in patients with type ... read more

Century-Old TB Vaccine Shows Promise Against Type 1 Diabetes, MGH Research Finds

A new study finds that an inexpensive vaccine used globally to prevent tuberculosis may help treat Type 1 diabetes — if given time to kick in. Six years after publishing phase 1 clinical trial results ... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials ... empagliflozin 2.5 mg and placebo and higher than placebo in adults with type 1 dia... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

and INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced that both randomized controlled trials ... in adults with type 1 diabetes on empagl... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us